Merck Says Earnings Suffered from Vioxx Withdrawal,
Sets Aside $600 Million for Defense Costs
February 1, 2005
WHITEHOUSE STATION, N.J. - Merck & Co., Inc. reported Jan. 25 that fourth quarter earnings dropped more than 20 percent compared to a year ago, due mostly to fallout from its decision to pull Vioxx from the market and the possible legal ramifications of the withdrawal.
The company reported earnings of $1.1 billion, about $300 million less than in the fourth quarter of 2003. Merck said the results were negatively affected by the loss of nearly $700 million in revenue that the drug maker would have anticipated earning had it not decided to voluntarily withdraw Vioxx from the market …
UPCOMING CONFERENCES

HarrisMartin's Data Breach Litigation Conference
March 26, 2025 - Charlotte, NC
Omni Charlotte Hotel